Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Table 3 Clinical and economic outcomes for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence (discounted by 3%)

Outcomes	CAZ-AVI sequence^a	Ceftolozane/Tazobactam sequence^b
% of patients with cure	93.04%	91.52%
% of patients died in hospital	5.02%	5.60%
% of patients with AE	6.12%	7.48%
Average number of days in hospital	13.04	13.42
LYs	4.411	4.384
QALYs	4.021	3.982
Drug costs	€ 2952	€ 2324
Hospitalisation costs	€ 11,355	€ 11,781
SAE costs	€ 185	€ 226
Recurrence costs	€ 0	€ 0
Total costs	€ 14,492	€ 14,331
Incremental cost per QALY gained	€ 4099

AE = adverse event; CAZ-AVI = ceftazidime-avibactam; LY = life year; QALY = quality-adjusted life year; SAE = serious adverse event.
^aCAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem
^bCeftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem